Lauren Stopfer
Executive Director of Proteomics & Innovation Aethon Therapeutics
Lauren Stopfer is the Executive Director of Proteomics & Innovation at Aethon Therapeutics, where she leads the development of advanced mass spectrometry-based workflows to identify and validate novel canonical and synthetic MHC antigens. Prior to Aethon, she was part of the Proteomics team at BioNTech, establishing specialized immunopeptidomics methods to support oncology and infectious disease programs.
Lauren earned her Ph.D. in Bioengineering from MIT. Her doctoral work helped establish “quantitative immunopeptidomics” by developing platforms for precise measurement of MHC-bound peptides. She holds a B.S. in Biomedical Engineering from the University of Wisconsin–Madison.
Seminars
Wednesday 4th February 2026
Quantitative Immunopeptidomics Drives Target Discovery & Rational Antibody Design for T Cell Engagers
11:00 am
- Exploring how high-sensitivity, targeted immunopeptidomics enable direct detection and detailed characterization of drug-modified (haptenated) peptide–MHC complexes, informing the rational design of bispecific T cell engagers with cross-HLA reactivity
- Outlining how the quantitative profiling of amplified MHC-I targets defines the therapeutic window and guides engineering of T cell engagers against canonical, mutation-agnostic epitopes such as pan-KRAS amplification
- Integrating immunoproteomics-driven target validation with antibody engineering to accelerate the development of next-generation T cell engagers, exemplified by programs targeting mutant KRAS, KRAS amplification, and p53 mutants
